Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Tech for Wellbeing: Applications and Devices for a Better You - 2More parents refusing vitamin K shots for newborns, study finds
- 3One lightly wounded after Iranian missile barrage targets northern Israel
- 4Novo Nordisk cuts Wegovy price in South Africa for a second time
- 5Study finds humans were making fire 400,000 years ago, far earlier than once thought
- South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- The 15 Best Business visionaries Under 40
- Sexual violence is being used as a weapon in Sudan's war, doctors group says
- Nexi expands alliance with PayPal
- 'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
- Safeguarding Your Senior Protection Against Extortion and Tricks.
- Astronauts welcome arrival of new crewmates | On the International Space Station this week Nov. 24-28, 2025
- A Manual for Well known Western television Series
- Figure out How to Alter Your Volvo XC40 for Further developed Solace
